Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report
This case illustrates the potential of OBZ as an effective therapeutic option in podocytopathies with RTX inadequate response. The superior efficacy of OBZ may result from enhanced antibody-dependent cellular cytotoxicity, depletion of tissue-resident B cells, and reduced immunogenicity compared with RTX. OBZ may thus offer an alternative in refractory MCD/FSGS.
Authors
- Nuno Oliveira (ORCID: https://orcid.org/0000-0002-4112-9236)
- João Venda (ORCID: https://orcid.org/0009-0006-5124-973X)
- Helena Sá
- Andreia Rita Henriques
- Emanuel Ferreira
Institutions
- Hospitais da Universidade de Coimbra (PT)
- University of Coimbra (PT)
Publication Details
- Journal
- Frontiers in Nephrology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.3389/fneph.2026.1772736
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00